EBR Systems, Inc (EBR) Fair Value & Analysis
Healthcare · AU · Market cap A$171M
Fair value as of: Jun 24, 2026
From 4 valuation models · updated 8 days ago
Share price +4.4% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.3153 – A$1.25 · fair‑value band A$0.1900 – A$0.3200 · the A$0.3750 price screens above the A$0.2600 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
EBR Systems, Inc (EBR) currently trades at A$0.3750, while our model-based Fair Value estimate is A$0.2600 — implying the stock looks roughly 30.7% overvalued today. We read business quality at 15/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$4.0M. Net debt stands at A$52.8M. Fundamentals as of Jun 24, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It offers WiSE cardiac resynchronization therapy system, an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads; and stimulation of the left ventricular endocardium for cardiac resynchronization therapy (SOLVE-CRT), an investigational device exemption. The company was incorporated in 2003 and is headquartered in Sunnyvale, California.
Revenue & earnings trend
FY2020 – FY2025 · reported fiscal years
EBR Systems, Inc reported revenue of A$1.7M in FY2025 versus A$0 in FY2020. Reported net income was −A$50.5M in FY2025.
Is EBR fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ABT ABT | 1,600 MXN | 82.40 MXN | -95% |
| Abbott Laboratories, ABTT34 | R$38.22 | R$30.39 | -20% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is EBR Systems, Inc (EBR) undervalued?
What is the fair value of EBR?
What is the quality score of EBR?
What is the revenue of EBR Systems, Inc (EBR)?
What is the net profit margin of EBR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.